Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

Lidt om fedme - Quick facts about obesity, weight loss


117157 Minino 9/12 2023 14:45
Oversigt

Lidt om fedme - Quick facts about obesity, weight loss


Preface: Hormone GLP-1 has received widespread scientific attention due to its involvement in insulin and blood sugar control. That's how a new class of medications was BORN, which are called GLP-1 agonists. These medications are typically given as injections (with the exception of semaglutide)
NB: GLP-1 is NOT the only hormone that affects blood sugar regulation and insulin production.
"Side effects" of GLP-1 agonists include weight loss and nausea (kvalme).

Approved GLP-1 agonists include:
Byetta/Bydureon (exenatide)
Victoza (liraglutide)
Lyxumia/Adlyxin (lixisenatide)
Tanzeum (albiglutide)
Trulicity (dulaglutide)
Ozempic/Wegovy (semaglutide injections)
Rybelsus (oral semaglutide - the only oral GLP-1 agonist)
Zepbound (tirzepatide; Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE.)

Other hormones that can be used for the treatment of type 2 diabetes and obesity: GIP (Gastric inhibitory polypeptide), GCGR (glucagon receptor). Zealand Pharma in Denmark studies on all 3 of them (see product pipeline).

1) What is glucagon-like peptide 1 (GLP-1) :
glucagon: a hormone formed in the pancreas which promotes the breakdown of glycogen to glucose in the liver.
peptides: two or more amino acids linked in a chain

Researchers describe Glucagon-Like Peptide-1 (GLP-1) as both a neuropeptide and an incretin.
A neuropeptide is a peptide compound that has an effect on the nervous system. An incretin is a metabolic hormone that helps maintain plasma glucose levels through regulation of insulin and glucagon

GLP-1 decreases appetite by acting on specific areas in the brain

What is GLP-1 & Does it Affect Weight & Cognition?
https://selfhacked.com/blog/glp-1-a-hormone-that-causes-weight-loss-and-good-cognitive-effects/

2) Is semaglutide a synthetic peptide?
Semaglutide is a synthetic peptide analog of the naturally occurring glucagon-like peptide-1 (GLP-1) hormone. As an incretin (hormones that are released from the gut into the bloodstream), GLP-1 triggers the release of pancreatic hormones like insulin in the human body, aiding in the regulation of blood sugar levels after meals

What are synthetic peptides made from?
Synthetic peptide vaccines are usually composed of 20-30 amino acids (aminosyrer) containing the specific epitope of an antigen related to infectious and/or chronic diseases including cancers.

3) which synthetics are used for making obesity drug
exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide injection, oral semaglutide, tirzepatide

4) Wegovy alternative?
https://www.healthline.com/health/drugs/wegovy-alternative
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7

Weight-loss drugs have been approved by the U.S. Food and Drug Administration (FDA) for long-term use:
Bupropion-naltrexone (Contrave)
Liraglutide (Saxenda)
Orlistat (Xenical, Alli)
Phentermine-topiramate (Qsymia)
Semaglutide (Wegovy)
Setmelanotide (Imcivree)
Tirzepatide (Zepbound)

And: GLP-1 agonist medications currently available on the U.S. market include:
Dulaglutide (Trulicity®).
Exenatide (Byetta®).
Exenatide extended-release (Bydureon®).
Liraglutide (Victoza®).
Lixisenatide (Adlyxin®).
Semaglutide injection (Ozempic®).
Semaglutide tablets (Rybelsus®).

https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists

5) which companies engaged in developing treatments for obesity?

A growing number of companies are engaged in developing innovative treatments for obesity. This is due to the increasing prevalence of obesity worldwide and the growing recognition of its significant health consequences. Here are some of the leading companies working on obesity treatments:

Novo Nordisk: Novo Nordisk is a Danish multinational pharmaceutical company that is a major player in the development of obesity treatments. The company's pipeline includes a variety of drugs that target different aspects of the obesity process, such as appetite control, metabolism, and gut hormones. Wegovy is their current heavyweight champion.

Eli Lilly and Company: Another major pharmaceutical company with a focus on obesity treatment. They are developing a variety of medications, including the GLP-1 agonist tirzepatide (Zepbound), as well as exenatide extended-release (Bydureon) and liraglutide (Saxenda).

Sanofi: A French multinational pharmaceutical company with a portfolio of obesity treatment options. They are developing the GLP-1 agonist dulaglutide (Trulicity), as well as the glucagon receptor agonist liraglutide (Saxenda).

Orexigen: OrexiGen Pharmaceuticals is a biopharmaceutical company that is developing a new class of drugs called dual orexin agonists for the treatment of obesity. Orexin is a brain hormone that plays a role in appetite regulation. Dual orexin agonists are designed to activate both of the orexin receptors, which is expected to be more effective than existing drugs that only activate one receptor.

ReShape Lifesciences: ReShape Lifesciences is a medical device company that is developing a minimally invasive procedure for treating obesity. The procedure involves implanting a balloon in the stomach to create a smaller gastric pouch. This is expected to help patients feel fuller faster and eat less.

Virta Health: Virta Health is a digital health company that is using technology to help patients manage their weight and improve their health. The company's approach combines a low-carbohydrate diet with personalized coaching and virtual care.

Allergan plc: An American multinational pharmaceutical company specializing in developing obesity treatments. They are developing the investigational drug lorcaserin (Belviq), a selective serotonin receptor agonist.

Gelesis: Gelesis is a biotechnology company that is developing a novel weight loss pill called Gelesis 100. The pill is made of a hydrogel that expands in the stomach to create a feeling of fullness.

These are just a few of the many companies that are working on obesity treatments. As the field of obesity research continues to advance, we can expect to see even more innovative and effective treatments in the years to come.

Here are some additional companies that are involved in obesity research and development:

Arena Pharmaceuticals
Agios Pharmaceuticals
Altimmune Inc (Pemvidutid, It is a synthetic peptide and is an analogue of oxyntomodulin)
Amgen (AMG-133)
Arsanis
AstraZeneca PLC (Shanghai company Eccogene)
Baxalta
BioMarin
Bristol Myers Squibb
Cerecor
Cholerica Pharmaceuticals
Coherus BioSciences
Corcept Therapeutics
Eisai
Nalpropion Pharmaceuticals
Orexigen Therapeutics
Pfizer (stop danuglipron Dec 2023)
Regeneron Pharmaceuticals
Roche (Carmot Therapeutics)
Sandoz (Orlistat)
Vivus Inc
Zealand Pharma (Dapiglutide, Survodutide)

I hope this information is helpful. Please let me know if you have any other questions.
/BARD GOOGLE

6) Last words from ChatGPT
5 ways to keep weight

Balanced Diet: Maintain a well-rounded diet with a mix of lean proteins, whole grains, fruits, vegetables, and healthy fats. Portion control is key to avoid overeating.
Regular Exercise: Engage in both cardiovascular exercises (e.g., jogging, swimming) and strength training to promote overall health and maintain muscle mass, which can help regulate weight.
Hydration: Drink an adequate amount of water daily, as staying hydrated supports overall health and can help control hunger, preventing overeating.
Mindful Eating: Pay attention to what and when you eat. Avoid distractions during meals and savor each bite. This can help you recognize when you're full and prevent unnecessary snacking.
Adequate Sleep: Ensure you get enough quality sleep each night. Lack of sleep can disrupt hormonal balance, leading to increased appetite and potential weight gain.

7) Appendix
BMI = weight (kg) / height(m)^2
https://www.calculator.net/bmi-calculator.html

ForeverWegoFree pills:
https://www.instagram.com/reel/CoFD6kUAxwb/
https://www.instagram.com/reel/C0HAMXCSgGs

GIP and GLP-1, the two incretin hormones: Similarities and differences:
https://onlinelibrary.wiley.com/doi/10.1111/j.2040-1124.2010.00022.x

HAPPY HEALTHY WORKOUTS and HH EATER :−)

facts, fedme, glp-1, insulin, obesity, sundhed, workouts

facts, fedme, glp-1, insulin, obesity, sundhed, workouts

facts, fedme, glp-1, insulin, obesity, sundhed, workouts




9/12 2023 17:07 ProInvestorNEWS 2117159



Video fra Helge Larsens besøg hos Dansk Aktionærforening i Roskilde torsdag 9. november 2023. Under besøget fortæller han om den globale fedmeepidemi og dens følgesygdomme som insulinresistens, diabetes, inflammation, hjerte-karsygdomme, Alzheimers m.m. Han kommer også ind på bivirkningerne ved fedmemedicin, og hvordan menneskets egen krop kan producere appetitdæmpende GLP1. Helge Larsen fortæller desuden om potentialet og udfordringerne i sundhedstrenden inden for for tarmbakterier.
Omtalte selskaber er Novo Nordisk, Eli Lily, Zealand Pharma, Chr. Hansen, Novozymes og Biogaia.

Disclaimer: Videoen er ikke en anbefaling om køb eller salg af aktier. Helge Larsen har aktier i Novo Nordisk, Eli Lily og Zealand Pharma.




TRÅDOVERSIGT